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The pregnane X receptor (PXR) has been well-established as a critical mediator in regulating important
drug metabolizing enzymes and transporter proteins, including cytochrome P450 3A4 (CYP3A4) and P-
glycoprotein (P-gp). Previous studies identiﬁed that PXR served as a molecular target of SUMOylation.
However, the impact of SUMOylation of PXR on its transcriptional activity in regulating the expression/
activity of the target genes is poorly investigated. In the current study, we established cell-based models
of SUMOylated PXR in LS174T cells to investigate the impact of SUMOylation of PXR on regulating the
expression/activity of CYP3A4 and P-gp. Our results revealed that rifampicin-induced PXR transactivation
of the CYP3A4 and P-gp promoter was suppressed by SUMOylation of PXR in reporter gene assay. The
mRNA and protein expression of CYP3A4 and P-gp was also suppressed. Moreover, CYP3A4 enzymatic
assay and Rho123 intracellular assay revealed that rifampicin-induced CYP3A4 and P-gp activity was also
suppressed by SUMOylated PXR. Our data collectively indicated for the ﬁrst time that SUMOylation of
PXR exerts suppressive effect on rifampicin-induced expression and activity of CYP3A4 and P-gp, which
suggest that alteration in the SUMOylation status of PXR will be expected to affect the CYP3A4 mediated
drug metabolism and P-gp mediated drug transport.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Drugedrug interactions (DDIs) have been identiﬁed as an
important clinical issue which cause change in systemic exposure
of drugs by other co-administered medication. A number of these
interactions are due to alterations in expression and activity of drug
metabolizing enzymes and transporter proteins, among whichodiﬁer; PXR, pregnane X re-
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3, rhodamine 123.
l Sciences, Sun Yat-sen Uni-
sity City, Guangzhou 510006,
.
Huang), bihchang@mail.sysu.
rmacological Society.
ution to this work. They are
. Production and hosting by Elsecytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) gained
the most investigation (1). CYP3A4, one of the major isozyme of
CYPs in humans, is abundantly expressed in liver and intestine. It
has broad substrate speciﬁcity responsible for biotransformation of
over 50% of all clinically prescribed drugs (2). P-gp, encoded by the
MDR1 gene in humans, belongs to the ATP-binding cassette (ABC)
superfamily. It is expressed in many tissues, including gastroin-
testinal epithelium and canalicular membrane of the liver (3). P-gp
is responsible for the efﬂux of xenobiotics from cells and therefore
plays a key role in inﬂuencing the pharmacokinetics of numerous
drugs (4). Alteration in the expression and activity of CYP3A4 or/
and P-gp may change the exposure and affect the response of many
administered drugs in patients (5).
The pregnane X receptor (PXR, NR1I2), predominately
expressed in liver and intestine, belongs to the superfamily of
ligand-activated transcriptional factors. To date, PXR has beenwell-
established as a critical mediator in regulating important drug
metabolizing enzymes (DMEs) and transporter proteins, includingvier B.V. This is an open access article under the CC BY-NC-ND license (http://
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may lead to profound up-regulation of CYP3A4 and/or P-gp-
mediated metabolism, transport, and elimination of potentially
toxic compounds from the body, and thus result in potential DDIs
(7). Recent studies have indicated an emerging role for post-
translational modiﬁcation of PXR in regulating multiple biochem-
ical pathways, including ubiquitylation, phosphorylation, acetyla-
tion, and SUMOylation (8).
SUMOylation is mediated by Small Ubiquitin-like Modiﬁers
(SUMO) which can be covalently attached to a broad range of
substrate proteins in eukaryotic cells. SUMOylation regulates
various cellular functions including proteineprotein interaction,
sub-cellular localization, regulation of DNA binding, etc (9). The
human genome contains three functional genes that encode SUMO
proteins called SUMO-1, SUMO-2, and SUMO-3. The SUMO
pathway constitutes a conserved enzymatic cascade which is
initiated by an ATP-dependent activation of the SUMO protein by a
SUMO-activating enzyme (also called E1). The activated SUMO
protein is then transferred to a SUMO-conjugating enzyme (E2
ligase) called Ubc9. Finally, the SUMO protein is further transferred
from Ubc9 to the lysine residue within the substrate with the
assistance of one of the several E3 SUMO protein ligases (10, 11).
SUMOylation of several nuclear receptors (NRs) such as peroxisome
proliferator-activated receptor a (PPARa), liver X receptor b (LXRb),
and retinoid-related orphan receptor a (RORa) has been demon-
strated to play critical roles in modulating their function. Specif-
ically, SUMOylation of NRs displays repression on their
transcriptional activity while some potentiate their transcriptional
activation, suggesting another perspective of the NR-mediated
regulation of their target genes (12e14). Most recently, it has
been reported that PXR could be SUMOylated via Ubc9 as E2
conjugating enzyme and PIAS4 as E3 ligases (8, 15). Therefore, it is
of particular interest to determine whether the transcriptional ac-
tivity of PXR and regulation of the expression/activity of its target
genes such as CYP3A4 and P-gp could be changed by SUMOylation.
In the current study, we transiently transfected PXR and SUMO-
related plasmids in LS174T cells to establish cell-based models of
SUMOylated PXR to study the impact of SUMOylation of PXR on
regulating the expression/activity of CYP3A4 and P-gp. Our data
revealed that SUMOylated PXR suppressed the RIF-induced tran-
scriptional activation and expression of CYP3A4 and P-gp. In
addition, RIF-induced CYP3A4 and P-gp activity was also sup-
pressed by SUMOylation of PXR.
2. Materials and methods
2.1. Chemicals and reagents
The pSG5-hPXR expression vector was provided by Dr. Steven
Kliewer (University of Texas Southwestern Medical Center, Dallas,
TX) (16). The pGL3-CYP3A4- XREM luciferase reporter construct
(17), pcDNA3-6His-SUMO3, plasmids p3258 (pCMV-hUBC9), and
pcDNA4-hismax-PIAS4 were provided by Dr. Jeff Staudinger (Uni-
versity of Kansas, Lawrence, KS). The tk-MDR1-Luc was from Dr.
Wen Xie (University of Pittsburgh, Pittsburgh, PA). The pRL-TK
Renilla luciferease control vector was obtained from Promega
(Madison, WI). Rifampicin (RIF) and dimethyl sulphoxide (DMSO)
were purchased from SigmaeAldrich (St. Louis, MO). All other
chemicals and solvents were commercially available and of
analytical grade.
2.2. Cell culture
LS174T cells (derived from Caucasian colon adenocarcinoma)
were purchased from Shanghai Institute for Biological Sciences cellresource center (Shanghai, China) and maintained in RPMI 1640
medium (Hyclone, Logan, UT, USA) supplemented with 10% FBS.
Both cell lines were cultured at 37 C under a humidiﬁed atmo-
sphere of 5% CO2.
2.3. Cell-based SUMOylation assays
The cell-based SUMOylation assays were performed using a
previously described method with slight modiﬁcation (15). Brieﬂy,
LS174T cells were grown for 24 h until 90% conﬂuence. Cells were
transfected with pSG5-hPXR, pcDNA3-6His-SUMO3, pCMV-hUBC9,
and pcDNA4-hismax-PIAS4 using Lipofectamine 2000 (Invitrogen)
according to the manufacturer's instructions. pcDNA3.1þ were
added as empty vectors. 48 h after transfection, cells were washed
with phosphate-buffered saline (PBS) and harvested in lysis buffer
(6 M guanidinium-HCl, 10 mM Tris, 100 mM sodium phosphate
buffer, pH 8.0). After sonication, the cell lysates were mixed with
Ni2þ-linked agarose (QIAGEN). The mixture was incubated for 2 h
on a rotator at room temperature and centrifuged to gather the
beads. The beads were then washed in wash buffer I (8 M urea,
10 mM Tris, and 100 mM sodium phosphate buffer, pH 8.0), II (8 M
urea, 10 mM Tris, 100 mM sodium phosphate buffer, pH 6.3, 0.1%
Triton X-100, and 5 mM b-mercaptoethanol), III (150 mM NaCl,
10 mM imidazole, and 50 mM sodium phosphate buffer, pH 6.75),
and PBS. The beads were then resuspended in 2*SDS-PAGE gel
loading buffer and samples were resolved on 10% SDS-PAGE for
Western blot analysis to detect the SUMOylated form of PXR using
the H-11 monoclonal anti-PXR antibody (Santa Cruz).
2.4. Transient transfection and reporter gene analysis
For transient transfection, LS174T cells were seeded in 6-well
plates at a density of 1.0  106 cells per well and grown for 24 h
until 80% conﬂuence. Cells in each well were transfected with 1 ug
of pSG5-hPXR, pcDNA3-6His-SUMO3, pCMV-hUBC9, and pcDNA4-
hismax-PIAS4. Various amounts of pcDNA3.1þ were added as
empty vectors to achieve 4 ug of total DNA per well. Six hours later,
the transfected cells were treated with either 0.1% DMSO or 10 mM
RIF for additional 24 h before following process.
For reporter gene analysis, LS174T cells were seeded in 96-well
plates at a density of 5.0  104 cells per well and grown for 24 h
until 80% conﬂuence. To measure PXR transactivation, cells in each
well were transfected with 60 ng of pGL3-CYP3A4-XREM-Luc (or
tk-MDR1-Luc), 30 ng of pSG5-hPXR, 30 ng of pcDNA3-6His-SUMO3,
30 ng of pCMV-hUBC9, 30 ng of pcDNA4-hismax-PIAS4, and 5 ng of
pRL-TK as an internal control. Various amounts of pcDNA3.1þwere
added as empty vectors to achieve 185 ng of total DNA per well. Six
hours later, the transfected cells were treated with either 0.1%
DMSO or 10 mM RIF for additional 24 h. Luciferase activities were
measured by a Dual Reporter Assay System (Promega). Transfection
efﬁciency was determined by Renilla luciferase activity, and the
ﬁreﬂy luciferase activity was determined and normalized against
Renilla luciferase activity.
2.5. Total RNA isolation and quantitative real-time polymerase
chain reaction analysis (qPCR)
Total RNA was isolated from LS174T cells using Trizol reagent
(Invitrogen, Grand Island, NY). After DNase I treatment, RNA was
reversely transcribed into cDNA using the PrimeScript™ RT reagent
Kit (Takara, Kyoto, Japan). Equal amounts of cDNA were used in
real-time quantitative polymerase chain reactions (rt-QPCRs). The
sequences (50 to 30) for the primers are as follows: CYP3A4, forward
primer (TCAGCCTGGTGCTCCTCTATCTAT), reverse primer
(AAGCCCTTATGGTAGGACAAAATATTT); P-gp, forward primer
Fig. 1. Detection of SUMOylated PXR protein in LS174T cells. LS174T cells were trans-
fected with different expression vectors as indicated in Materials and methods. Cells
were lysed using denaturing buffer containing guanidinium hydrochloride to inacti-
vate de-SUMOylation enzymes. SUMOylated proteins were puriﬁed by using nickel-
linked agarose beads. The blot was probed for PXR immunoreactivity using a mono-
clonal antibody that recognizes the human PXR protein.
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CACAATGCAG); and GAPDH (human), forward primer
(GGATTTGGTCGTATTGGG), reverse primer (GGAA-
GATGGTGATGGGATT). RT-QPCR was performed using a SYBR Pre-
mix Ex Taq II (Tli RnaseH Plus) kit (TaKaRa Biotech) in an Applied
Biosystems 7500 Real-Time PCR System (Applied Biosystems, Fos-
ter City, CA). Cycling conditions were 95 C for 30s followed by 40
cycles of 95 C for 5 s, 60 C for 20 s, and 40 C for 60 s. The fold
induction was calculated as described previously (18).
2.6. Western blotting analysis
Western blot analysis was performed as described previously
(19). Brieﬂy, transfected LS174T cells were incubated with DMSO
(0.1%) or Rifampicin (10 mM) for 48 h. Protein extracted from cells
was then prepared using RIPA lysis buffer containing EDTA and
protease inhibitors, and quantiﬁed by BCA protein assay (Thermo
Scientiﬁc, Rockford, IL). Protein samples were then separated on
8%e12% SDS-PAGE and electrophoretically transferred onto poly-
vinylidene ﬂuoride membranes (Millipore, Bedford, USA) that were
probed with primary antibodies including CYP3A4 (SC-53850), P-
gp (SC-13131) (Santa Cruz Biotechnology) and GAPDH (14C10) (Cell
Signaling Technology). Immunodetection was performed using an
enhanced chemiluminescence (ECL) detection kit (Engreen Bio-
system, Beijing, China) and analyzed using the ImageJ software
(National Institute of Health, Bethesda, MD).
2.7. CYP3A4 enzymatic assay
Transfected LS174T cells were treated with 0.1% DMSO or 10 mM
RIF for 48 h. The culture mediumwas then removed, replaced with
medium containing midazolam (MDZ) (40 mM) and cultured for
additional 4 h. Subsequently, tert-butyl methyl ether/dichloro-
methane (75:25, v/v), ammonia/water (1:30, v/v), and digitoxin
(3 mg/ml) as the internal standard (IS) were added to the cells with
culture medium for liquideliquid extraction. The metabolite was
extracted by centrifugation. The supernatant was then evaporated
and the residue was dissolved in methanol/H2O (containing 5 mM
ammonium formate and 0.1% formic acid) (8:2, v/v). The activity of
CYP3A4 was measured by the formation of 10-hydroxymidazolam
(10-OHMDZ) using a previously described LC-MS/MS method with
slight modiﬁcation (20, 21). Brieﬂy, the samples were analyzed
using Ultimate 3000 UPLC system (Dionex Corporation, Sunnyvale,
CA) interfaced with triple quadrupole mass spectrometer (TSQ
Quantum Access, Thermo Fisher Scientiﬁc, Waltham, MA). Chro-
matographic separations were performed on an XTerra MS C18
column (50 mm  2.1 mm, i.d., 3.5 mm, Waters) at room tempera-
ture. The samples were eluted with methanol/H2O (8:2, v/v) at a
ﬂow rate of 0.2 ml/min. The total running timewas 3.0 min for each
sample. Electrospray positive ionization mode (ESIþ) was used for
10-OHMDZ analysis. Selective reaction monitoring (SRM) experi-
ments using m/z 342.02/ 168.01 and 782.67/ 635.24 was per-
formed to monitor and quantitate 10-OHMDZ and IS, respectively.
2.8. Rho123 intracellular assay
Transfected LS174T cells were incubated with DMSO (0.1%) or
Rifampicin (10 mM) for 48 h. 2 mg/ml of Rh123 was then added to
the cells, which were incubated in the dark at 37 C under a hu-
midiﬁed atmosphere of 5% CO2 for additional 1 h. To measure the
intracellular accumulation of Rh123, the mean ﬂuorescence in-
tensity (MFI) associated with Rh123 was determined by Mono-
chromators Based Multimode Microplate Reader with excitation/
emission wavelengths of 485/535 nm.2.9. Statistical analysis
Data are presented as the mean ± SEM and expressed as fold
change over the DMSO treated group transfected with empty vec-
tor. One-way analysis of variance (ANOVA) was performed for
statistical comparison of the results, which was followed by LSD-t
test using GraphPad Prism (GraphPad Software Inc., San Diego,
CA). The criterion of signiﬁcance was set at P < 0.05 (*P < 0.05,
**P < 0.01, ***P < 0.001).
3. Results
3.1. SUMOylation of PXR suppressed RIF-induced PXR
transactivation of the CYP3A4 and P-gp promoter in reporter gene
transfected cells
First, we conﬁrmed that PXR could be SUMOylated by SUMO3
with the assistance of Ubc9 as E2 conjugating enzyme and PIAS4 as
E3 ligases in cell-based assay (Fig. 1). Dual-luciferase reporter as-
says were then used to evaluate the effect of SUMOylation on PXR
transactivation of the CYP3A4 or P-gp promoter in reporter gene
transfected LS174T cells. As shown in Fig. 2, treatment with RIF in
PXR-overexpressed cells largely induced the reporter activities of
CYP3A4-luc (Fig. 2A) and MDR1-luc (Fig. 2B) when compared to
those of the DMSO treated cells, indicating the successfully con-
struction of models for assessing PXR transactivation. The reporter
activity was not affected by over-expression of SUMO cascade
(SUMO3, UBC9, and PIAS4) alone. However, over-expressing SUMO
cascade signiﬁcantly suppressed the RIF-induced CYP3A4 and P-gp
reporter activities in PXR-transfected cells. These results indicated
that SUMOylation of PXR exhibits suppressive effect on RIF-induced
PXR transactivation of CYP3A4 and P-gp promoter.
3.2. SUMOylation of PXR suppressed the RIF-induced mRNA and
protein expression of CYP3A4 and P-gp
To investigate whether the suppressive effect of SUMOylated
PXR was also exerted on RIF-induced gene expression of CYP3A4
and P-gp, the mRNA levels of CYP3A4 and P-gp in transfected LS174T
cells were measured by qPCR. As expected, treatment with RIF
markedly induced the mRNA expression of CYP3A4 (19.13 ± 5.02
Fig. 2. Effect of SUMOylated PXR on RIF-induced PXR transactivation of CYP3A4 and P-gp promoter in reporter gene transfected cells. The LS174T cells were transfected with pGL3-
CYP3A4-XREM-Luc (A) or tk-MDR1-Luc (B) reporter gene construct and different expression vectors as indicated in Materials and methods. Cells were treated with vehicle control
(0.1% DMSO) or RIF (10 mM) for 24 h. Luciferase activity was then determined. Data are expressed as fold change over the DMSO treated group transfected with empty vector. P
values (**P < 0.01, ***P < 0.001) indicate statistically signiﬁcant when RIF-treated cells in PXR þ SUMO-transfected group were compared to RIF-treated cells in PXR-transfected
group (n ¼ 4).
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DMSO treated PXR-overexpressed cells. A statistically signiﬁcant
decrease in the RIF-induced CYP3A4 (P < 0.01) and P-gp (P < 0.05)
mRNA level was observed when SUMO cascade was co-expressed
in the PXR-overexpressed cells (Fig. 3A and B).
We next examined the protein level of CYP3A4 and P-gp in
transfected LS174T cells using Western blot analysis. Protein
expression of both CYP3A4 and P-gp was induced by RIF treatment
in PXR-overexpressed cells. A statistically signiﬁcant decrease in
the RIF-induced CYP3A4 and P-gp protein levels (P < 0.05) was
observed when SUMO cascade was co-expressed (Fig. 3C and D).
Taking together, in addition to the promoter activity, SUMOylationFig. 3. Effect of SUMOylated PXR on RIF-induced mRNA and protein expression of CYP3A4 an
in Materials and methods. Cells were treated with DMSO (0.1%) or RIF (10 mM) for 24 h or 48
are expressed as fold change over the DMSO treated group transfected with empty vector.
treated cells in PXR þ SUMO-transfected group were compared to RIF-treated cells in PXR-of PXR also suppressed RIF-induced gene and protein expression of
CYP3A4 and P-gp.
3.3. SUMOylation of PXR suppressed the RIF-induced activity of
CYP3A4 and P-gp
As SUMOylation of PXR suppresses RIF-induced expression of
CYP3A4 and P-gp on gene and protein level, it is interesting to know
whether the CYP3A4 enzymatic activity and P-gp transporter ac-
tivity are also affected. The CYP3A4 enzymatic activity was deter-
mined by measuring the formation of 1’-hydroxymidazolam (10-
OHMDZ), the metabolite of typical CYP3A4 substrate midazolamd P-gp. The LS174T cells were transfected with different expression vectors as indicated
h, and then CYP3A4 and P-gp mRNA (AeB) or protein (CeD) levels were analyzed. Data
P values (*P < 0.05, **P < 0.01, ***P < 0.001) indicate statistically signiﬁcant when RIF-
transfected group (n ¼ 3).
Fig. 4. Effect of SUMOylated PXR on RIF-induced CYP3A4 enzymatic activity and P-gp transporter activity. LS174T cells were transfected with different expression vectors as
indicated in Materials and methods. Cells were treated with DMSO (0.1%) or RIF (10 mM) for 48 h, and then CYP3A4 and P-gp activity was analyzed. (A) Representative and
comparative SRM chromatograms of 10-OHMDZ metabolized by CYP3A4 in LS174T cells. (B and C) Data are expressed as fold change over the DMSO treated group transfected with
empty vector. P values (*P < 0.05) indicate statistically signiﬁcant when RIF-treated cells in PXR þ SUMO-transfected group were compared to RIF-treated cells in PXR-transfected
group (n ¼ 3).
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with RIF yielded 2.02 ± 0.40 fold of 10-OHMDZ compared to that in
DMSO treated PXR-overexpressed cells, which was consistent with
the expression level of CYP3A4. A statistically signiﬁcant decrease
in the RIF-induced CYP3A4 (P < 0.01) enzymatic activity level was
observed when SUMO cascade was co-expressed in the PXR-
overexpressed cells.
To determine whether P-gp activity was also decreased after
SUMOylation of PXR, we conducted accumulation experiment by
recruiting ﬂuorescent dye Rh123, a speciﬁc substrate of P-gp. PXR-
overexpressed cells treated with RIF resulted in 34.19 ± 11.14%
decrease of intercellular Rho123 compared to that in DMSO treated
PXR-overexpressed cells, whereas only 13.45 ± 9.73% decrease of
intercellular Rho123 could be observed when SUMO cascade was
co-expressed in the PXR-overexpressed cells (Fig. 4C). Taken
together, these results were generally consistent with those
observed in the reporter assay, qPCR and Western blot.
4. Discussion
Increasing evidences have implicated that drugedrug in-
teractions or multidrug resistance related to loss of drug thera-
peutic efﬁcacy or safety are caused by PXR-mediated
transactivation of diverse drug-metabolizing enzymes or drug
transporters (22). CYP3A4 and P-gp, both of which are well-
characterized PXR target genes, represent the two most impor-
tant determinants responsible for the unfavorable DDIs or even
fatal adverse drug reactions. Therefore, evaluation of regulatory
factors involved in altering PXR transcriptional activity of CYP3A4
and P-gp has evolved to be extremely important. The mechanism
underlying PXR transactivation of CYP3A4 and P-gp involves ligand
binding to PXR which in turn results in binding to the response
element within the promoter of a target gene. The process requires
heterodimerization between PXR and retinoid X receptor (RXR) for
high-afﬁnity DNA binding (23).
In addition to the well-characterized prototypical ligand-
mediated transcriptional activation of PXR, recent study revealed
that PXR undergoes SUMOylation by incorporation of SUMO3
chains to repress inﬂammatory response. However, the effect of
SUMO modiﬁcation on PXR-target gene activation and subsequent
biochemical functions are still largely unknown. It has been re-
ported that the transcriptional activity of key members of the nu-
clear receptor superfamily were changed upon SUMOylation (12,
13). For example, SUMOylation of PPARa had a negative effect on
its transcription activity through selective recruitment of core-
pressor NcoR (12). Zhang et al. showed that SUMO modiﬁcation
could impair LXRb binding to its target DNA sequence, which mayserve as a possible mechanism for the suppressive effect on LXR-
mediated gene activation. Speciﬁcally, SUMO cascades decreased
the abundance of LXRb bound to the Srebp1c promoter containing
LXR response element, thereby suppressing its transactivation of
target genes (14). Nevertheless, data from luciferase reporter gene
assay suggested that overexpression of SUMO3 and Ubc9 had no
impact on PXR transactivation in CV-1 cells (15), which was con-
trary to our results of the current study.
In our study, we transiently transfected PXR and SUMO cascade-
related plasmids including SUMO3, UBC9, and PIAS4 in LS174T cells
for studying the impact of SUMOylation on PXR transcriptional
activity. We ﬁrst conﬁrmed that PXR could be SUMOylated by
SUMO3with the assistance of Ubc9 and PIAS4 in cell-based assay. It
was interesting to notice that PXR without SUMOylation could also
be detected with PXR antibody in Western blotting. As PXR protein
contains two zinc ﬁnger motifs, and zinc and nickel share similar
properties as metals, it is possible that nickel in afﬁnity columns
mimics the zinc and interact with PXR proteins. We then investi-
gated the role of SUMO modiﬁcation in PXR transactivational ac-
tivity of CYP3A4 andMDR1 by using a luciferase reporter gene assay.
We found that overexpression of SUMO3, UBC9, and PIAS4 can
signiﬁcantly suppress the PXR-mediated RIF-induced CYP3A4 and
MDR1 reporter activity. Previous studies indicated that UBC9, the
only E2 enzyme identiﬁed, is sufﬁcient for covalent attachment of
SUMO to speciﬁc substrates in vitro. However, E3 ligases are still
essential for protein SUMOylation, which may particularly enhance
the efﬁciency and selectivity of SUMO attachment to target sub-
strates (24e26). It is noteworthy that members of Protein Inhibitor
of Activated STAT (PIAS) family are known SUMO E3 ligases with
the RING ﬁnger domain indispensable for its activity (25). In
addition to PIAS family proteins, other structurally different types
of RING-containing proteins also exhibit E3 ligase activity in
SUMOylation reactions, which may provide a possible illustration
for various SUMOylation status of speciﬁc substrates in different
cells. A study pioneered by Dahle et al. indicated that enhancing
SUMOylation by cotransfection of PIAS4 suppressed both basal and
Myb-induced level of reporter activation. The basal level of
SUMOylation in CV-1 cells was signiﬁcantly enhanced by over-
expression of PIAS4 when compared to that without PIAS4 (26).
Therefore, PIAS4 may increase the SUMOylation of PXR, in which
way that the suppressive effect of SUMOylation on PXR-mediated
gene activation could be observed in our study. Next, we
employed qPCR, Western blot analysis, and activity assay for
CYP3A4 and P-gp, to verify the suppressive effect of SUMOylated
PXR on RIF-inducible expression and activity of CYP3A4 and P-gp.
Based on the well-described characteristics of PXR transcrip-
tional activation of CYP3A4 and P-gp, further studies could be
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derlying the suppressive effect of SUMOylated PXR on its function.
The attachment of SUMO protein to the lysine residues within PXR
may interfere the binding of ligands to the ligand-binding domain
(LBD) of the receptor, and possibly increase the strength of inter-
action between PXR and the co-repressor proteins such as nuclear
receptor co-repressor (NCoR), while inhibit the recruitment of co-
activator proteins such as steroid receptor co-activators (SRC1
and SRC2). Moreover, SUMOylation may alter the PXR activity by
disrupting the heterodimerization with retinoid X receptor a
(RXRa) and subsequent binding to the responsive element in the
promoter of the target genes. Nevertheless, experimental animals
can also be employed as useful in vivomodels for future research in
addition to immortalized cell lines.
A number of studies in experimental animals have shown that
systemic inﬂammation and acute infection are capable of down-
regulating the activities and/or expression of drug-metabolizing
enzymes (27, 28). Pronounced changes in the expression of ABC
transporters including P-gp have also been reported in classic
models of the inﬂammatory response (29e31). As activation of
inﬂammation strongly promotes the SUMOylation statues of PXR
(15), it is of particular interest to reveal whether SUMOylated PXR
acts as the molecular basis underlying the suppression of DMEs and
transporter proteins in response to inﬂammation. In the current
study, we identiﬁed that SUMOylation of PXR suppresses the RIF-
induced expression and activity of CYP3A4 and P-gp, which may
provide a plausible mechanism for down-regulated expression
and/or activities of DMEs and transporter proteins under
inﬂammation.
In summary, our results revealed for the ﬁrst time the sup-
pressive effects of SUMOylated PXR on the RIF-induced expression
and activity of CYP3A4 and P-gp. Therefore, alteration in the
SUMOylation status of PXR will be expected to affect the CYP3A4
mediated drug metabolism and P-gp mediated drug transport.
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